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Summary
Probiotics, live cells with different beneficiary characteristics, have been extensivelly
studied and explored commercially in many different products in the world. Their benefits
to human and animal health have been proven in hundreds of scientific research. Lactoba-
cillus and Bifidobacterium are the main probiotic groups; however, there are reports on the
probiotic potential of Pediococcus, Lactococcus, Bacillus and yeasts. Some of the identified
probiotic strains exhibit powerful anti-inflammatory, antiallergic and other important pro-
perties. Apart from that, the consumption of dairy and non-dairy products stimulates the
immunity in different ways. Various food matrices have been used with probiotics, which
are briefly documented. In this review, the history of probiotics, their application in the
health and food areas and new trends in probiotic products and processes are presented.
Key words: probiotics, intestinal microflora, Bifidobacterium, Lactobacillus, immune stimula-
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Introduction
Probiotic is a relatively new word meaning 'for life',
which is used to name microorganisms that are associ-
ated with the benefical effects for humans and animals.
These microorganisms contribute to intestinal microbial
balance and play a role in maintaining health. The pro-
biotic microorganisms consist mostly of the strains of the
genera Lactobacillus and Bifidobacterium, but strains of Ba-
cillus, Pediococcus and some yeasts have also been found
as suitable candidates. Together they play an important
role in the protection of the organism against harmful
microrganisms and also strengthen the host's immune
system. Probiotics can be found in dairy and non dairy
products. They are usually consumed after the antibiotic
therapy (for some illnesses), which destroys the micro-
bial flora present in the digestive tract (both the useful
and the targeted harmful microbes). Regular consump-
tion of food containing probiotic microorganisms is re-
commended to establish a positive balance of the popu-
lation of useful or beneficial microbes in the intestinal flora.
The global market of probiotic ingredients, supple-
ments and food was worth $14.9 billion in 2007 and it
was expected to reach 15.9 billion in 2008, and 19.6 bil-
lion in 2013, representing a compound annual growth
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rate of 4.3 % (1). Extensive investigations of probiotics
have been greatly enhanced by the research of new mi-
crobes for future probiotic bacteriotherapy applications.
The scope of this manuscript is to review the definition,
history, applications, production, technology and future
trends of probiotics.
Probiotics: What Are They?
The name probiotic comes from the Greek 'pro bios'
which means 'for life'. The history of probiotics began
with the history of man; cheese and fermented milk
were well known to the Greeks and Romans, who re-
commended their consumption, especially for children
and convalescents. Probiotics are defined as the living
microorganisms administered in a sufficient number to
survive in the intestinal ecosystem. They must have a
positive effect on the host (2). The term 'probiotic' was
first used by Lilly and Stillwell (3) in 1965 to describe
the 'substances secreted by one microorganism that sti-
mulate the growth of another'. A powerful evolution of
this definition was coined by Parker in 1974 (4), who
proposed that probiotics are 'organisms and substances
which contribute to intestinal microbial balance' (5). In
more modern definitions, the concept of an action on
the gut microflora, and even that of live microorganisms
disappeared. Salminen et al. (6) defined probiotics as the
'food which contains live bacteria beneficial to health',
whereas Marteau et al. (7) defined them as 'microbial
cell preparations or components of microbial cells that
have a beneficial effect on the health and well-being'.
Some modern definitions include more precisely a pre-
ventive or therapeutic action of probiotics. Charteris et
al. (8), for example, defined probiotics as 'microorga-
nisms which, when ingested, may have a positive effect
in the prevention and treatment of a specific pathologic
condition'. Finally, since probiotics have been found to
be effective in the treatment of some gastrointestinal
diseases (7), they can be considered to be therapeutic
agents. It is clear that a number of definitions of the
term 'probiotic' have been used over the years but the
one derived by the Food and Agriculture Organization
of the United Nations/World Health Organization (9)
and endorsed by the International Scientific Association
for Probiotics and Prebiotics (10) best exemplifies the
breadth and scope of probiotics as they are known to-
day: 'live microorganisms which, when administered in
adequate amounts, confer a health benefit on the host'.
This definition retains historical elements of the use of
living organisms for health purposes but does not re-
strict the application of the term only to oral probiotics
with intestinal outcomes (11).
Despite these numerous theoretical definitions,
however, the practical question arises whether a given
microorganism can be considered to be a probiotic or
not. Some strict criteria have been proposed. Havenaar
et al. (12), for example, proposed the following para-
meters to select a probiotic: total safety for the host,
resistance to gastric acidity and pancreatic secretions,
adhesion to epithelial cells, antimicrobial activity, inhi-
bition of adhesion of pathogenic bacteria, evaluation of
resistance to antibiotics, tolerance to food additives and
stability in the food matrix. The probiotics in use today
have not been selected on the basis of all these criteria,
but the most commonly used probiotics are the strains
of lactic acid bacteria such as Lactobacillus, Bifidobacter-
ium and Streptococcus (S. thermophilus); the first two are
known to resist gastric acid, bile salts and pancreatic en-
zymes, to adhere to colonic mucosa and readily colonize
the intestinal tract (5).
The history of probiotics
The origin of cultured dairy products dates back to
the dawn of civilization; they are mentioned in the Bible
and the sacred books of Hinduism. Climatic conditions
for sure favoured the development of many of the tra-
ditional soured milk or cultured dairy products such as
kefir, koumiss, leben and dahi (13). These products,
many of which are still widely consumed, had often
been used therapeutically before the existence of bac-
teria was recognized (14).
At the beginning of the 20th century the main func-
tions of gut flora were completely unknown. Ilya Ilyich
Metchnikoff, the Nobel prize winner in Medicine in 1908,
at the Pasteur Institute linked the health and longevity
to ingestion of bacteria present in yoghurt (15,16). He
believed that the constitution of the human body pre-
sented several disharmonies inherited from primitive
mammals, such as body hair, wisdom teeth, stomach,
vermiform appendix, caecum, and large intestine. In
1907, he postulated that the bacteria involved in yoghurt
fermentation, Lactobacillus bulgaricus and Streptococcus
thermophilus, suppress the putrefactive-type fermentations
of the intestinal flora and that consumption of these
yoghurts played a role in maintaining health. Indeed, he
attributed the long life of Bulgarian peasants to their
intake of yoghurt containing Lactobacillus species (16). In
particular, he reported that the large intestine, useful to
mammals in managing rough food composed of bulky
vegetables, is useless in humans. Moreover, it is the site
of dangerous intestinal putrefaction processes which can
be opposed by introducing lactobacilli into the body,
displacing toxin-producing bacteria, promoting health,
and prolonging life (17).
Tissier's discovery of bifidobacteria in breast-fed
infants also played a key role in establising the concept
that specific bacteria take part in maintaining health. In
1906, Tissier reported clinical benefits from modulating
the flora in infants with intestinal infections (18). At the
time, many others were sceptical about the concept of
bacterial therapy and questioned in particular whether
the yoghurt bacteria (L. bulgaricus) were able to survive
intestinal transit, colonize and convey benefits (19). In
the early 1920s, L. acidophilus milk was documented to
have therapeutic effects, in particular, a settling effect on
digestion (20). It was believed that colonization and
growth of these microorganisms in the gut were essen-
tial for their efficacy, and therefore, the use of intestinal
isolates was advocated. In Japan in the early 1930s, Shi-
rota focused his research on selecting the strains of in-
testinal bacteria that could survive passage through the
gut and on the use of such strains to develop fermented
milk for distribution in his clinic. His first product con-
taining L. acidophilus Shirota (subsequently named L.
casei Shirota) was the basis for the establishment of the
Yakult Honsha company (21).
414 C.R. SOCCOL et al.: The Potential of Probiotics, Food Technol. Biotechnol. 48 (4) 413–434 (2010)
Only at the end of the century, it became clear that
intestinal microflora had several functions, including
metabolic, trophic and protective ones (22). Metabolic
functions are primarily characterized by the fermenta-
tion of non-digestible dietary residue and endogenous
mucus, savings of energy as short-chain fatty acids, pro-
duction of vitamin K, and absorption of ions. Trophic
functions are based on the control of epithelial cell proli-
feration and differentiation, and development and homeo-
stasis of the immune system. Finally, protective func-
tions are connected with the barrier effect and protection
against pathogens (17). The health benefits derived from
the consumption of foods containing Lactobacillus acido-
philus, Bifidobacterium and L. casei are now well docu-
mented. Streptococcus thermophilus and L. delbrueckii ssp.
bulgaricus are yoghurt starter cultures, which offer some
health benefits; however, they are not natural inhabi-
tants of the intestine. Therefore, for yoghurt to be consi-
dered as a probiotic product, L. acidophilus, Bifidobacte-
rium and L. casei are incorporated as dietary adjuncts.
Thus, the normal practice is to make a product with
both starter organisms, e.g. S. thermophilus and L. delbru-
eckii ssp. bulgaricus, and one or more species of probiotic
bacteria (23).
The guidelines that stipulate what is required for a
product to be called a probiotic were published by FAO/
WHO in 2002 (24). They require that strains be desig-
nated individually, speciated appropriately and retain a
viable count at the end of their shelf life in the desig-
nated product formulation that confers a proven clinical
end-point. The probiotic definition requires that the effi-
cacy and safety of probiotics be verified and thus, as-
sessment of this constitutes an important part of their
characterization for human use (25).
Probiotic Microorganisms
The probiotic potential of different bacterial strains,
even within the same species, differs. Different strains of
the same species are always unique, and may have dif-
fering areas of adherence (site-specific), specific immu-
nological effects, and actions on a healthy vs. an in-
flamed mucosal milieu may be distinct from each other.
Current probiotic research aims at the characterization
of the normal, healthy gut microbiota in each individual,
assessing the species composition as well as the concen-
trations of different bacteria in each part of the intestine.
The target is to learn to understand host–microbe inter-
actions within the gut, microbe–microbe interactions
within the microbiota and the combined health effects of
these interactions. The goal is to define and characterize
the microbiota both as a tool for nutritional manage-
ment of specific gut-related diseases and as a source of
new microbes for future probiotic bacteriotherapy appli-
cations. This may eventually include organisms specifi-
cally isolated to provide site-specific actions in disorders
such as the irritable bowel syndrome (25).
According to Shah (23) and Chow (26) the most po-
pular strains are represented by the following genera:
Lactobacillus, Streptococcus, and Bifidobacterium (Table 1,
27–38), but other organisms including enterococci and
yeasts have also been used as probiotics. Some of these
strains have been chosen based on selection criteria (12)
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Table 1. Commercial probiotic microorganisms
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Adapted from Gismondo et al. (2), Shah (23) and Chow (26)
that are believed to be important for their efficacy such
as origin of strain, in vitro adherence to intestinal cells
(39–41) and survival during passage through the gastro-
intestinal tract (42–45).
The genus Bifidobacterium
Bifidobacteria were first isolated and described in
1899–1900 by Tissier, who described rod-shaped, non-
-gas-producing, anaerobic microorganisms with bifido-
bacterial morphology, present in the faeces of breast-fed
infants, which he termed Bacillus bifidus. Bifidobacteria
are generally characterized as Gram-positive, non-spore-
-forming, non-motile and catalase-negative anaerobes
(46). They have various shapes including short, curved
rods, club-shaped rods and bifurcated Y-shaped rods. Pre-
sently, 30 species are included in the genus Bifidobacter-
ium, 10 of which are from human sources (dental caries,
faeces and vagina), 17 from animal intestinal tracts or
rumen, two from wastewater and one from fermented
milk (47).
Bifidobacteria are microorganisms of paramount im-
portance in the active and complex ecosystem of the in-
testinal tract of humans and other warm-blooded ani-
mals, as well as of honeybees (46). They are distributed
in various ecological niches in the human gastrointes-
tinal and genitourinary tracts, the exact ratio of which is
determined mainly by the age and diet. The indigenous
microflora of infants is dominated by bifidobacteria,
which are established shortly after birth. Their prolife-
ration is stimulated by the glycoprotein components of
k-casein in human colostrum and, to a lesser extent, hu-
man milk. The number of bifidobacteria decreases with
increasing age of an individual and eventually becomes
the third most abundant genus (accounting for approx.
25 % of the total adult gut flora) after the genera Bac-
teroides and Eubacterium (48).
The genus Lactobacillus
In 1990, Moro was the first researcher to isolate a
strain which he typified as Bacillus acidophilus, a generic
name for intestinal lactobacilli. Lactobacilli are in gene-
ral characterized as Gram-positive, non-spore-forming
and non-flagellated rods or coccobacilli (49). They are
either aerotolerant or anaerobic and strictly fermenta-
tive. Glucose is fermented predominantly to lactic acid
in the homofermentative case, or equimolar amounts of
lactic acid, CO2 and ethanol (and/or acetic acid) in the
heterofermentative counterpart. Gomes and Malcata (47)
reported that 56 species of the genus Lactobacillus have
been recognized.
Lactobacilli are distributed in various ecological
niches throughout the gastrointestinal and genital tracts
and constitute an important part of the indigenous mi-
croflora of man and higher animals. Their distribution is
affected by several environmental factors, which include
pH, oxygen availability, level of specific substrates, pre-
sence of secretions and bacterial interactions. They are
rarely associated with cases of gastrointestinal and extra-
intestinal infection, and strains employed technological-
ly are regarded as non-pathogenic and safe microorga-
nisms. Furthermore, they have the reputation of health
promoters, especially in the human gastrointestinal and
genitourinary tracts (50).
Other Probiotic Microorganisms
Although the term probiotic is more related to lactic
acid bacteria as Lactobacillus and Bifidobacterium, it can
be extended to other microorganisms which have not
been explored. For example, Bacillus species have been
used as probiotics for at least 50 years in an Italian pro-
duct commercialized as Enterogermina® (2·109 spores).
Among this group some species that have been evalu-
ated are Bacillus subtilis, Bacillus clausii, Bacillus cereus,
Bacillus coagulans and Bacillus licheniformis (51). Some
advantages of the bacterial spores are their resistance to
heat, allowing the storage at room temperature and in a
dried form. Also, these bacteria are able to reach small
intestine since they survive the gastric pH of the sto-
mach (52). The application of probiotic bacterial spores
ranges from dietary supplements to growth promoters
and uses in aquaculture (e.g. shrimp) (51).
Probiotic formulations involving some Bacillus spe-
cies are recommended for use with antibiotics since
these strains are resistant to them (e.g. B. clausii) (53). B.
coagulans has been used as adjunct therapy for relieving
rheumatoid arthritis (54). B. subtilis has been researched
genetically and physiologically, and is strongly associat-
ed with a Japanese product known as natto. The con-
sumption of this product can lead to stimulation of the
immune system and reduction of blood coagulation by
fybrinolysis (55,56). The secretion of antimicrobials such
as coagulin, amicoumacin and subtilisin is also verified
in Bacillus.
The proposed mechanisms for probiotic effects of
the Bacillus spores are based on immunomodulation,
which occurs through the stimulation of the gut-associ-
ated lymphoid tissue (GALT) by production of cyto-
kines, competitive exclusion of gastrointestinal patho-
gens (e.g. competition for adhesion sites) and secretion
of antimicrobial substances (57).
Several studies have been performed to assure the
safety of Bacillus species using animal models and in
vitro tests to evaluate the toxicity or adverse effects of
the strains. The use of B. subtilis is approved for use as a
supplement in Italy and the UK. However, the designa-
tion 'probiotic' should only be allowed if the microorga-
nism presents the characteristics inherent to probiotic
strains. On the other hand, studies of competitive exclu-
sion of Escherichia coli 078:K80 by Bacillus subtilis (58)
and the suppression of Vibrio harveyi in shrimp by sev-
eral Bacillus spore formers (59) have strongly shown the
probiotic potential of these strains.
Probiotic microorganisms used in animal prepara-
tions are Enterococcus, Bacillus, Streptococcus, Lactobacillus,
Aspergillus and Saccharomyces (60). Vitacanis® is a probio-
tic formulation which can be used in preventing intes-
tinal disorders in dogs and cats. Among Enterococcus
species, Enterococcus faecium is the most used in com-
mercial probiotics. The presence of Enterococcus faecium
is important in preventing infection by Salmonella enter-
ica ssp. enterica ser. Typhimurium (61). Additionally, a
probiotic product known as Causido®, which contains S.
thermophilus and E. faecium, has been proposed for a
short-term hypocholesterolaemic effect (62). Interesting
characteristics of the Enterococcus group are the survival
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on dry surfaces for prolonged periods and the resistance
to antibiotics (63).
Among the probiotic yeasts, the most common ge-
nus is Saccharomyces, which has been employed in live-
stock feed. S. cerevisiae has shown a beneficial effect when
administrated in the Nile tilapia as growth promoter
(64). The potential probiotic effect of S. cerevisiae and S.
cerevisiae var. boulardii has been demonstrated since they
are able to tolerate low pH and bile and protect against
bacterial infections through the reduction of the intes-
tinal pro-inflammatory response (65). However, the ad-
hesion properties of these yeasts should be better invest-
igated.
Safety
In theory, probiotics may be responsible for four
types of side effects in susceptible individuals: systemic
infections, deleterious metabolic activities, excessive im-
mune stimulation, and gene transfer (66,67). In practice,
however, lactobacilli and bifidobacteria (and probiotics
based on these organisms) are extremely rare causes of
infections in humans (6,68,69). This lack of pathogenicity
extends across all age groups and also to immunocom-
promised individuals (70).
Traditional dairy strains of lactic acid bacteria (LAB)
have a long history of safe use. LAB, including different
species of Lactobacillus and Enterococcus, have been con-
sumed daily since humans started to use fermented milk
as food. Probiotic species such as Lactobacillus acidophilus
have been safely used for more than 70 years. However,
the safety aspects always have to be considered and
possible adverse effects should be continuously evalu-
ated, as illustrated by recent literature. Members of the
genera Lactococcus and Lactobacillus are most commonly
given the GRAS status, whilst members of the genera
Streptococcus, Enterococcus and some other genera of LAB
are considered opportunistic pathogens.
The safety of probiotics has been considered in re-
views and clinical reports which have drawn attention
to isolate cases of human bacteraemia (71–73). Surveil-
lance studies support the safety of commercial LAB
(71,73,74). Available data indicate that no harmful effects
have been observed in controlled clinical studies with
lactobacilli and bifidobacteria (6).
Three approaches can be used to assess the safety of
a probiotic strain: studies on the intrinsic properties of
the strain, studies on the pharmacokinetics of the strain
(survival, activity in the intestine, dose–response relation-
ships, faecal and mucosal recovery) and studies search-
ing for interactions between the strain and the host.
The Joint FAO/WHO Expert Consultation on Evalu-
ation of Health and Nutritional Properties of Probiotics
in Food Including Powder Milk with Live Lactic Acid
Bacteria recognized the need for guidelines to set out a
systematic approach for the evaluation of probiotics in
food in order to substantiate the health claims. Conse-
quently, a Working Group was convened by FAO/WHO
to generate guidelines and recommend criteria and meth-
odology for the evaluation of probiotics, and to identify
and define what data need to be available to accurately
substantiate health claims. The aims of the Working Group
were to identify and outline the minimum requirements
needed for probiotic status. Then, guidelines were pre-
pared in 2002 to meet this objective. These guidelines
are available in: Joint FAO/WHO Working Group Re-
port on Drafting Guidelines for the Evaluation of Pro-
biotics in Food (24).
Quantification of probiotics
Traditionally, appropriate dilutions of faecal samples
have been cultured on selective media. However, the se-
lectivity of any medium is at best relative and these
methods are prone to both false-positive and false-ne-
gative results (75). More importantly, not all microbes
can be cultured by the currently available techniques.
With the advent of molecular biology, culture-inde-
pendent techniques have been developed. In particular,
methods using the variable and conserved regions of the
16S rRNA have proved successful in characterizing the
gut microbiota. The use of 16S rRNA enables enumera-
tion of microbes which are either unculturable by the
current cultivation techniques or have died during trans-
port and storage (75). Fluorescent in situ hybridization
(FISH) is commonly used and employs species-, genus-
or domain-specific fluorescently labelled 16S rRNA probes
(76). Enumeration of the labelled microbes can be done
microscopically by visual counting (77), which is, how-
ever, laborious. On the other hand, although image anal-
ysis of the microscopic view makes it possible to process
a relatively large number of samples, this is expensive
(78). Alternatively, enumeration of fluorescent microbes
can be done by flow cytometry, which similarly allows
the analysis of large numbers of samples, but is also ex-
pensive (79). Techniques based on the polymerase chain
reaction (PCR) are also commonly used and provide ra-
pid quantitative and qualitative information on the com-
position of the intestinal microbiota (25).
Mechanisms of action
The mechanisms by which probiotics exert biologi-
cal effects are still poorly understood, but the nonspe-
cific terms such as colonization resistance or competitive
exclusion are often used to explain their mode of action
(39). Colonization resistance or competitive exclusion de-
scribes a phenomenon whereby the indigenous anaero-
bic flora limits the concentration of potentially pathoge-
nic (mostly aerobic) flora in the digestive tract (80). The
concept of competitive exclusion was first developed
during the early 1970s when it was discovered that the
administration of mixed adult intestinal microorganisms
conferred adult-type resistance against Salmonella infec-
tion to newly hatched chicks (81).
Oelschlaeger (82) reported that the effects of probio-
tics may be classified in three modes of action: (i) Pro-
biotics might be able to modulate the host's defences in-
cluding the innate as well as the acquired immune system.
This mode of action is most likely important for the pre-
vention and therapy of infectious diseases but also for
the treatment of (chronic) inflammation of the digestive
tract or parts thereof. In addition, this probiotic action
could be important for the eradication of neoplastic host
cells; (ii) Probiotics can also have a direct effect on other
microorganisms, commensal and/or pathogenic ones. This
principle is in many cases of importance for the preven-
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tion and therapy of infections and restoration of the
microbial equilibrium in the gut; (iii) Finally, probiotic
effects may be based on actions affecting microbial pro-
ducts like toxins and host products, e.g. bile salts and
food ingredients. Such actions may result in inactivation
of toxins and detoxification of host and food components
in the gut. The same author also stated that the kind of
effect(s) a certain probiotic executes depends on its me-
tabolic properties, the molecules presented at its surface
or on the components secreted. Even integral parts of
the bacterial cell such as DNA or peptidoglycan might be
of importance for its probiotic effectiveness. The indi-
vidual combination of such properties in a certain pro-
biotic strain determines a specific probiotic action and as
a consequence its effective application for the prevention
and/or treatment of a certain disease.
Probiotics and Human Health
Nowadays, consumers are aware of the link among
lifestyle, diet and good health, which explains the emerg-
ing demand for products that are able to enhance health
beyond providing basic nutrition. The list of health be-
nefits accredited to functional food continues to increase
and the probiotics are one of the fastest growing cate-
gories within food for which scientific researches have
demonstrated therapeutic evidence. Among several the-
rapeutic applications of the probiotics can be cited the
prevention of urogenital diseases, alleviation of con-
stipation, protection against traveller's diarrhoea, reduc-
tion of hypercholesterolaemia, protection against colon
and bladder cancer, prevention of osteoporosis and food
allergy (83). One of the most studied strains, Bifidobac-
terium lactis, has been used in several types of studies to
demonstrate its probiotic ability, and scientific evidence
for this strain has been cited in many reviews (84–88).
Ingestion of LAB has been suggested to confer a
range of health benefits including immune system mo-
dulation (89,90), increased resistance to malignancy (91)
and infectious illness (92). Maldonado Galdeano et al.
(93) studied the effect of fermented milk containing Lac-
tobacillus casei DN114001, which induced mucosal im-
mune stimulation reinforcing the non-specific barrier
and modulating the innate immune response in the gut,
maintaining the intestinal homeostasis.
Host immune modulation is one of the suggested
benefits of the consumption of probiotic functional food.
However, comparative studies on the immunological
properties that support the selection of strains of the
same species for specific health benefits are limited.
Medina et al. (94) evaluated the ability of different strains
of Bifidobacterium longum to induce cytokine production
by peripheral blood mononuclear cells. B. longum live
cells of all strains induced specific cytokine patterns,
suggesting that they could drive immune responses in
different directions. Kelly et al. (95) demonstrated the
ability of species within the commensal microflora to
modulate immune function. Arunachalam et al. (96) stu-
died the dietary consumption of B. lactis HN019 and
concluded that a relatively short-term dietary regime (6
weeks) is sufficient to impart measurable improvements
in immunity. Chiang et al. (97) demonstrated that die-
tary consumption of probiotics in oligosaccharide-rich
substrate enhanced immune function by B. lactis HN019
in a different range for two types of leucocytes. In vivo
and in vitro indices of immunity in healthy mice fed with
Lactobacillus rhamnosus (HN001, DR20), L. acidophilus
(HN017) and B. lactis (HN019, DR10) were examined by
Gill et al. (98) and the results suggested that supplemen-
tation of the diet with these strains was able to enhance
several indices of natural and acquired immunity.
Infectious diseases are still the biggest human health
problem for the world to solve. Intestinal infection caused
by the intake of pathogenic microorganisms with the con-
taminated water and food are the main causes of death.
Under this circumstance, probiotics can assist in part the
foodborne problematic situation, as it is demonstrated in
several studies. Shu and Gill (99) demonstrated that B.
lactis HN019 can reduce the severity of infection caused
by the enterohemolytic pathogen Escherichia coli O157: H7
and suggested that this reduction may be associated
with enhanced immune protection conferred by the pro-
biotic. B. lactis HN019 also demonstrated the ability to
provide a significant degree of protection against Salmo-
nella infection by enhancing various parameters of im-
mune function that are relevant to the immunological
control of salmonellosis (100). Moreover, the same au-
thors suggested that dietary treatment using B. lactis
HN019 could reduce the severity of weanling diarrhoea
associated with rotavirus and E. coli, possibly via a me-
chanism of enhanced immune-mediated protection. As a
consequence, probiotic treatment might be an effective
dietary means of preventing or limiting diarrhoea in hu-
man infants (101).
The intestinal barrier maintains the epithelial inte-
grity protecting the organism against bacterial or food
antigens that could induce inflammatory processes lead-
ing to intestinal disorders such as inflammatory bowel
diseases (IBD) (102). Probiotic microorganisms compete
with pathogenic bacteria for epithelial binding sites,
avoiding the colonization by Salmonella sp. and E. coli
strains (103,104). In order to investigate the host-microbe
interactions, the co-cultivation of intestinal bacteria with
immune and/or intestinal epithelial cells (IEC) has been
performed. This technique allows the evaluation of the
importance of these interactions on barrier function,
cytokine expression, bacterial recognition and pathogen
invasion. Ukena et al. (105) demonstrated that E. coli
Nissle 1917 (EcN 1917) strain was capable of inducing
pro-inflammatory cell responses, since the co-incubation
of Caco-2 cells with E. coli EcN 1917 resulted in the up-
regulation of 126 genes, including the monocyte chemo-
attractant protein-1 ligand 2 (MCP-1), macrophage inflam-
matory protein-2a (MIP-2a) and macrophage inflammatory
protein-2b (MIP-2b). Recent data have shown that EcN
1917 prevented the disruption of the mucosal barrier by
enteropathogenic E. coli and restored the mucosal inte-
grity in T84 epithelial cells (106).
L. casei ssp. rhamnosus has shown to be a promising
probiotic in preventing the colonization of the gastroin-
testinal tract by pathogenic bacteria such as enteropatho-
genic E. coli, enterotoxigenic E. coli, and Klebsiella pneu-
moniae using in vitro model with Caco-2 cell line (107).
There are several reports about the action of the
probiotics against Helicobacter pylori (108–110), a Gram-
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-negative bacterium associated with the development of
chronic gastritis, peptic ulcers and gastric cancer. It was
reported that L. salivarius inhibited the colonization and
the release of interleukin-8 in gnotobiotic mice inoculat-
ed with H. pylori (111).
Clinical studies have suggested the efficacy of the
administration of probiotics in maintaining the remis-
sion of the pouchitis (112), ulcerative colitis (113), and
Crohn's disease (114). Patients suffering from ulcerative
colitis (UC) were treated with Escherichia coli Nissle 1917
(115,116) and Lactobacillus rhamnosus GG (117) and the
results were similar to that of the standard medication
(5-aminosalicylic acid – Mesalazine). When infants were
fed with a supplemented formula containing Lactobacil-
lus reuteri 55730 or Bifidobacterium lactis, there was a de-
crease in the cases of diarrhoea (118). In vivo assays with
probiotic bacteria evaluated the effects of an acute or chro-
nic gut inflammation using dextran sulphate sodium
(DSS), which induces colitis in mice, presenting positive
results (119).
Anti-carcinogenic effect of probiotics coming from
in vivo studies in both men and animals was evaluated.
Furthermore, in vitro studies with carcinoma cell lines
and anti-mutagenicity assays also supported this effect.
The anti-carcinogenic effect may be attributable to a
combination of mechanisms such as the induction of
pro-inflammatory, anti-inflammatory or secretory re-
sponses that might inhibit carcinogenesis. The strain-
-dependent variability, such as the immune modulation
effect, complicates the understanding of the role of im-
munity in probiotic-mediated anti-carcinogenesis. Fur-
ther work is needed to assess the long-term effects of
probiotics on the host's immunity in relation to anti-car-
cinogenesis. Immune-based anticancer therapies have
not yet demonstrated their efficacy because few clinical
trials have been done (120).
Lactobacillus and Bifidobacteria strains and E. coli strain
Nissle 1917 have shown anti-mutagenic activities in vi-
tro, probably due to their capacity to metabolize and
inactivate mutagenic compounds (121). Cytoplasmic frac-
tions of L. casei YIT9029 and B. longum HY8001 showed
the ability to suppress the proliferation of tumor cells
when administrated orally to mice as dietary supplement
(122). Other bacteria stimulated the immune system. It
was found that L. casei strain Shirota, when administ-
ered intranasally in mice, stimulated the cell immune
response by induction of interleukin-12, interferon-gamma
and tumour necrosis factor alpha, which all have an im-
portant role in excluding influenza virus (123). Roller et
al. (91) correlated the inhibition of carcinogenesis in rats
with changes in the immune activity, in response to pro-
biotic consumption. Furthermore, the protective role of
probiotics in rodent models of colon carcinogenesis can
be found in some other studies (124–126). Studies in ani-
mal models also suggest that increasing natural killer
cell activity by probiotic consumption may have poten-
tial effects on delayed tumour development. For example,
Takagi et al. (127) used dietary Lactobacillus casei strain
Shirota to inhibit methylcholanthracene-induced tumour
devolopment in mice and Varcoe et al. (128) investigated
the efficacy of the Lactobacillus acidophilus NCFM in pre-
venting gastrointestinal disease like overt colonic hyper-
plasia in mice.
Studies have suggested that probiotics could protect
against allergies. Isolauri et al. (129) evaluated the effect
of the hydrolysed whey formulas supplemented with
probiotics (B. lactis Bb12 and L. rhamnosus GG) in 27
breast-fed infants that suffered from atopic eczema. These
authors found that clinical signs and symptoms of atop-
ic eczema were diminished after two months in both
groups. Further, Kalliomäki et al. (130) performed a ran-
domised controlled-placebo trial with 132 pregnant wo-
men with any degree of occurrence of an atopic disease
such as atopic eczema, allergic rhinitis or asthma. These
mothers received two capsules of a formulation contain-
ing Lactobacillus GG for 2–4 weeks and the newborn
were administered the same formulation for 6 months
postnatally. The children were examined during the first
2 years. The results showed that the frequency of the
atopic eczema was only 23 % in the probiotic group
against 46 % in the placebo group. These works re-
ported great perspectives in using probiotic products in
the prevention of different allergies.
Some bacterial species are recognised for their capa-
city to prevent or limit mycotoxinogenic mould growth
such as Lactobacillus (131,132), Lactococcus (133), Pedio-
coccus (134) and Leuconostoc (135). The probiotic strain
Saccharomyces boulardii confers protection against toxin A
produced by Clostridium difficile and prevents intestinal
injury and inflammation. This is possible because S. bou-
lardii inhibits the activation of extracellular signal-regu-
lated ½ (ERK ½) and mitogen-activated protein (MAP)
kinases, thus modulating host signalling pathways (136).
In addition, mice that were fed with S. boulardii and im-
munized with C. difficile toxin A showed an increase in
specific intestinal anti-toxin A levels (137), which could
lead to protection against diarrhoeal diseases.
It has been reported that lactic acid bacteria are able
to bind aflatoxin B1 in vitro and in vivo (138), but this
property seems to depend on bacterial strain (139). Com-
pared to L. plantarum and L. fermentum, L. casei was re-
ported to be the strongest binder of aflatoxin (140). Also,
microorganisms such as Saccharomyces cerevisiae demon-
strated good ability to bind this aflatoxin (141). In the
study of Gratz et al. (142) rats received doses of aflatoxin
B1 and were fed with oral gavage containing Lactobacil-
lus rhamnosus strain GG (ATCC 53013). After adminis-
tration, an increase in the aflatoxin B1 in fecal excretion
was observed due to bacterial binding. The probiotic treat-
ment prevented weight loss and reduced the hepatotox-
ic effects of the aflatoxin B1.
Microcystins are toxins produced by freshwater cya-
nobacteria which can cause acute hepatoxicity and act as
tumour promoters (143). The probiotics Lactobacillus rham-
nosus strain GG and Bifidobacterium lactis strain Bb12
have demonstrated the ability to bind to microcystin-LR,
the most common and most toxic variant of microcys-
tins. A higher removal of microcystin-LR was observed
when Lactobacillus rhamnosus strain GG was heat-treated
(46 %) (144).
Recent studies have also suggested that probiotics
could have beneficial effects beyond some metabolic
disorders such as hypertension. Primary hypertension is
caused by various factors and the predominant causes
include hypercholesterolemia (145). Rising evidence has
indicated that lactobacilli and bifidobacteria could cause,
419C.R. SOCCOL et al.: The Potential of Probiotics, Food Technol. Biotechnol. 48 (4) 413–434 (2010)
when ingested, a significant reduction in serum choles-
terol. This is because cholesterol synthesis mainly occurs
in the intestines, hence the gut microflora promote effects
on lipid metabolism. Some studies demonstrated that
probiotics could promote a decrease in the blood cho-
lesterol levels and increase the resistance of low-density
lipoprotein to oxidation, therefore leading to a reduced
blood pressure (146).
Liong and Shah (147), using in vitro experiments, re-
ported that cholesterol could be removed from a me-
dium by L. acidophilus not only through assimilation
during growth, but also through binding of cholesterol
to the cellular surface. This mechanism was proposed
when both non-growing cells and dead cells were also
found to remove cholesterol. Another hypocholesterole-
mic mechanism described involves the ability of certain
probiotic strains to enzymatically deconjugate bile acids
through bile salt hydrolase catalysis. Enzymatic activity
was detected in the gut microflora such as Lactobacillus
and Bifidobacterium sp. (147,148). Since cholesterol is the
precursor for the synthesis of new bile acids, the use of
cholesterol to synthesize new bile would lead to a de-
creased concentration of cholesterol in blood (145). Ngu-
yen et al. (149) evaluated L. plantarum PH04 as a poten-
tial probiotic with cholesterol-lowering effect in mice.
Kaushik et al. (150) demonstrated that the indigenous L.
plantarum Lp9 exhibited cholesterol-lowering properties.
B. longum SPM1207 reduced serum total cholesterol and
LDL levels significantly, and slightly increased serum
HDL (151).
Cavallini et al. (152) observed the effects of Ente-
rococcus faecium CRL183, a mixture of isoflavones and
simvastatin (drug used to treat hypercholesterolemia),
on lipid parameters and atherosclerosis development in
rabbits with induced hypercholesterolemia. E. faecium
strain could be used to improve the lipid profile as an
alternative or an adjuvant to drug therapy. Placebo-con-
trolled studies (57,153–156) evaluate the effects of pro-
biotic strains on cholesterol metabolism in hyperchole-
sterolemia-induced mice and rats. It was found in all
these works that the serum cholesterol levels decreased
in the rats fed with a diet supplemented with probiotics.
Environment and lifestyle such as high-fat diet are
some of the factors that play a key role in the develop-
ment of obesity. Recent advances have identified the gut
microbiota as one such environmental factor that modu-
lates host energy and lipid metabolism. However, the
molecular mechanisms of these complex host-microbe
interactions have not been well identified (157). Most of
the data obtained have been done in experimental ani-
mal studies, but promising effects are also shown in hu-
mans, thereby supporting the interest in the nutritional
modulation of the gut microbiota in the management of
metabolic diseases in obese patients. The observations of
Cani et al. (158) suggest that increased levels of bifido-
bacteria may decrease intestinal permeability and lower
the circulating levels of endotoxin. High-fat feeding re-
duces the numbers of bifidobacteria, which have many
physiologically positive effects, including improved mu-
cosal barrier function. Supplementing the diet of high-
-fat fed mice with prebiotics restores the levels of bifi-
dobacteria and decreases endotoxaemia. Tanida et al. (159)
found that long-term ingestion of Lactobacillus paracasei
ST11 (NCC2461) reduced body and abdominal fat mass.
Their results suggest that L. paracasei NCC2461 has an
anti-obese action, and in this mechanism, autonomic
nerves may function to facilitate the lipolytic and ther-
mogenic responses via the sympathetic excitation and to
suppress the parasympathetic nerve activity in rats.
Probiotics also convert milk protein into bioactive
peptides, which have anthihypertensive effect. Milk pep-
tides may exert antihypertensive effects also through other
mechanisms, such as inhibition of the release of endo-
thelin-1 by endothelial cells, stimulation of the brady-
kinin activity, enhancement of the endothelium-derived
nitric oxide production and enhancement of the vasodi-
latory action of binding to opiate receptors. Angiotensin
I-converting enzyme (ACE), a dipeptidyl carboxypepti-
dase, catalyzes the conversion of angiotensin I to the po-
tent vasoconstrictor angiotensin II and plays an import-
ant physiological role in regulating blood pressure and
fluid and salt balance in mammals. ACE inhibitory pep-
tides from caseins and whey proteins are termed caso-
kinins and lactokinins, respectively. In vivo studies have
demonstrated that several ACE inhibitory peptides sig-
nificantly reduce blood pressure, either after intravenous
or oral administration (160–162). The hypotensive and
immunomodulatory peptides Val-Pro-Pro and Ile-Pro-Pro,
for example, can be released from precursor proteins by
enzymes from Lactobacillus helveticus. These peptides
could be applied as initial treatment in mildly hyper-
tensive individuals or as supplemental treatment. They
would also represent a low-cost alternative treatment for
hypertension.
Probiotics in Food and Beverages
As it was reported by Chow (26), the notion that
food could serve as medicine was first conceived thou-
sands of years ago by the Greek philosopher and father
of medicine, Hippocrates, who once wrote: 'Let food be
thy medicine, and let medicine be thy food'. However,
during recent times, the concept of food having medi-
cinal value has been reborn as 'functional foods'. A pro-
biotic may also be a functional food (156).
Functional foods are defined as: 'foods that contain
some health-promoting component(s) beyond traditional
nutrients'. Functional foods are also known as designer
foods, medicinal foods, nutraceuticals, therapeutic foods,
superfoods, foodiceuticals, and medifoods. In general,
the term refers to a food that has been modified in some
way to become 'functional'. One way in which foods can
be modified to become functional is by the addition of
probiotics (24).
New food products have been formulated with the
addition of probiotic cultures. Different types of food ma-
trices have been used such as various types of cheese,
ice creams, milk-based desserts, powdered milk for new-
born infants, butter, mayonnaise, powder products or
capsules and fermented food of vegetable origin (163).
Dairy products
In the production of probiotics an important factor
is the food substrate. Besides buffering the bacteria
through the stomach, it may contain functional ingre-
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dients that interact with the probiotics, altering their ac-
tivities. Fat content, type of protein, carbohydrates and
pH can affect probiotic growth and survival.
Dairy products are especially considered as ideal
vehicle for delivering probiotic bacteria to the human
gastrointestinal tract. The matrices used most frequently
are cheese, yoghurt, ice cream and other dairy products,
as shown in Table 2.
The most common means to incorporate probiotics
to fermented milk include: (i) addition of probiotics to-
gether with the starter cultures (DVI culture); (ii) the
production of two batches separately, one containing the
probiotic microorganism in milk to achieve a high con-
centration of viable cells and another with starter cul-
tures. When the fermentation stages are completed, the
batches are mixed; (iii) the use of a probiotic microorga-
nism as a starter culture. In this situation, the time of
fermentation is generally higher than traditional proces-
ses using non-probiotic starter cultures (163). In this
respect, it is necessary to consider the supplementation
of the culture medium and the production conditions
(e.g. incubation temperatures), since metabolites pro-
duced by probiotics can lead to off-flavours (164,165). In
addition, the probiotic strains must be compatible with
starter cultures, since the latter could produce inhibitory
substances that damage the probiotics (166).
Yoghurts with high fat content showed inhibitory
effects against probiotic cultures, particularly B. bifidum
BBI (167). The supplementation with vitamins (e.g. as-
corbic acid) has been reported to improve the viability
of L. acidophilus in yoghurts (168). The addition of sub-
stances such as whey protein may also enhance the via-
bility of some probiotics, probably due to their buffering
property. In addition, the employment of prebiotics in
yoghurt formulations could stimulate the growth and
activity of probiotics. In this regard, fructooligossacha-
rides showed to be most effective in maintaining the
probiotic viability (169).
The utilization of probiotics in the cheese elabora-
tion presents some challenges: low moisture content;
presence of salt; starter cultures competing for nutrients
and developing acid and flavour during the maturation
stage; extended storage (over 3 months), which can in-
fluence biochemical activities, redox potential, and alter
the cheese structure. Moreover, probiotics should sur-
vive the entire shelf life of the cheese, not produce meta-
bolites that affect the cheese quality and the starter cul-
ture activities, and also, they should be able to grow in
starter culture media (e.g. whey-based and phage inhi-
bitory media). Several studies related by Tamime et al.
(163) reported that Turkish white brined, Feta-type, Ched-
dar, Philippine white soft, Edam, Emmental, Domiati,
Ras, Herrgård cheese, Quarg, and cheese-based dips can
be compared with yoghurts in delivering probiotics.
The proteolytic patterns can be influenced by the
addition of probiotic strains. Ong et al. (170) reported
that the addition of probiotic microorganisms (L. acido-
philus 4962, L. casei 279, B. longum 1941, L. acidophilus
LAFTI® L10, L. paracasei LAFTI® L26, B. lactis LAFTI®
B94) as dairy starter adjuncts has lead to high concen-
tration of free amino acids by a secondary proteolysis
during ripening, and this was reduced when the cheese
was stored at 4 oC. It was found that all probiotic strains
survived the manufacturing process and produced a
level of acetic acid higher than the control Cheddar
cheese.
Other vehicles that could be used to deliver probiotics
are ice cream and frozen dairy desserts. These products
have the advantage to be stored at low temperatures,
which makes them less exposed to abusive temperatures
having higher viability at the time of consumption (171).
Besides, they are consumed by people of all ages and
are composed of milk proteins, fat and lactose as well as
other compounds that are required for bacterial growth.
However, some probiotic species showed a decrease in
the viability during the manufacture and freezing of ice
cream (172). Some prebiotics could be used to improve
the characteristics of the probiotic ice creams. Inulin de-
monstrated to be beneficial to the firmness, melting pro-
perties and dripping time of the ice creams (173). Be-
sides, the inulin level in ice cream enhanced the viability
of L. acidophilus and B. lactis (174). The addition of oligo-
fructose in low-fat ice cream also improved the survival
of L. acidophilus La-5 and B. animalis ssp. lactis Bb-12
during storage at –18 °C for 90 days (173). However, to
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Table 2. Commercial probiotic dairy products on the European market
Type of product Trade name Probiotic microorganism
Fermented milk with
high viscosity
Bifisoft, Bifidus, Bioghurt, Biofit, BiofardePlus, Biola,
Biologic bifidus, Cultura Dofilus, Dujat Bio Aktiv,
Ekologisk Jordgubbs Yoghurt, Fit&Aktiv, Fjäll Yoghurt,
Gaio Dofilus, Gefilac, Gefilus, LC 1, Probiotisches
Joghurt, ProViva, RELA, Verum, Vifit Vitamel, Vitality,
Weight Watchers, Yogosan Milbona
L. acidophilus, L. acidophilus LA5, L. rhamnosus
(LGG, LB21 and 271), L. casei, L. casei L19,
L. johnsonii, L. plantarum 299v, L. reuteri,
Lactococcus lactis ssp. lactis L1A, B. bifidum,
B. animalis ssp. lactis BB-12, B. animalis ssp.
animalis




A-fil, Actimel, Aktifit, AB-piimä, Bella Vita, Bifidus,
Biofit, Biola, Casilus, Cultura, Emmifit, Everybody,
Fit&Aktiv, Fundo, Gaio, Gefilac, Kaiku Actif, LC 1 Go!,
LGG+, Onaka, Öresundsfil, Philura, Probiotic drink,
ProViva, Pro X, Verum, ViktVäktarna, Vitality,
Le'Vive+, Yakult, Yoco Acti-Vit
L. acidophilus, L. acidophilus LA5, L. casei (F19,
431, Imunitas, Shirota), L. rhamnosus (LGG,
LB21 and 271), L. johnsonii, L. plantarum 299v,
L. reuteri, L. fortis, Lactococcus lactis ssp. lactis
L1A, B. bifidum, B. animalis ssp. lactis BB-12,




Gefilus, God Hälsa, RELA, Vivi Vivo L. rhamnosus LGG, L. plantarum 299v,
L. reuteri
From Tamime et al. (163)
efficiently produce probiotic ice cream, it is important to
select oxygen-resistant strains since the incorporation of
air (overrun) in the mixture occurs in the production
process, which is harmful to microaerophilic and an-
aerobic strains such as Lactobacillus sp. and Bifidobacter-
ium sp. This type of challenge can be resolved by the
use of microencapsulation technique. As an alternative,
aerated dairy dessert (e.g. chocolate mousse) has also been
used as a potential agent to deliver probiotics (175).
Non-dairy products
Some limitations of the use of dairy products to de-
liver probiotics are the presence of allergens and require-
ment of cold environments. This fact has led to the
launch of new products based on non-dairy matrices.
Some claims related to probiotic products are lactose
intolerance and fat content.
Some matrices have been used in the development
of non-dairy probiotic products such as fruits, vege-
tables, legumes and cereals. Fruits and vegetables can be
considered good matrices since they contain nutrients
such as minerals, vitamins, dietary fibres, and antioxi-
dants. The development of different probiotic fruit juices
has been studied (176,177). Prado et al. (178) described a
revision about a variety of non-dairy probiotic beve-
rages.
However, the incorporation of probiotics in fruit
juices requires the protection against acid conditions.
This can be achieved by microencapsulation technolo-
gies, which allow the entrapment of cells into matrices
with a protective coating. Gelatin and vegetable gum have
been demonstrated to provide a good protection for
acid-sensitive Bifidobacterium and Lactobacillus (179–181).
Encapsulation processes in milk protein have also been
studied (182). When B. lactis were microencapsulated,
incorporated into African fermented beverages (amasi
and mahewu) and assayed for physiological conditions
of the stomach, they showed a high survival rate, i.e. the
microencapsulation enhanced the viability in compari-
son with free cells (183).
Probiotic strains usually found in vegetable materi-
als are species belonging to Lactobacillus and Leuconostoc
genera. L. plantarum, L. casei and L. delbrueckii, for example,
were able to grow in cabbage juice without nutrient
supplementation and reached 108 CFU/mL after 48 h of
incubation at 30 oC (184). In addition, it was found that
these same bacteria grew in beet juice (185).
In the case of cereals, the fermentation with probio-
tic microorganisms could be beneficial due to the de-
crease of nondigestible carbohydrates (poly- and oligo-
saccharides), the improvement of the quality and level
of lysine, the availability of the vitamin B group, as well
as the degradation of phytates and release of minerals
(e.g. manganese, iron, zinc, and calcium) (186). Oat-based
substrates have proved promissory for the growth of L.
reuteri, L. acidophilus and B. bifidum (187). In addition,
cereals such as oats and barley contain high levels of
b-glucan, which is believed to have hypocholesterolemic
effect (188). Boza, an acid and low-alcohol beverage pro-
duced in the Balkan Peninsula, is a fermented product
based on maize, wheat and other cereals. Todorov et al.
(189) studied the microflora of boza and verified the pre-
sence of several lactic acid bacteria with probiotic char-
acteristics.
Malt, wheat and barley extracts demonstrated to have
a good influence in increasing bile tolerance and viabil-
ity of L. acidophilus, L. reuteri and L. plantarum (190,191).
Fermented foods with probiotic strains had an incre-
ment in the content of the vitamin B complex. Arora et
al. (192) found an enhancement of 14 and 11 % in thia-
mine and niacin contents, respectively, when food mix-
ture based on germinated barley flour with whey pow-
der and tomato pulp were autoclaved and fermented by
L. acidophilus. Also, non-germinated and germinated
mixture showed an increase of 31 and 34 % in lysine
content, respectively, after autoclaving and fermentation,
highlighting the importance of the germination and fer-
mentative process on the bioavailability and improve-
ment of the nutritional quality of foods.
Soybean is an important cereal because it has a high
nutritive value. However, the unpleasant bean flavour
and the content of oligosaccharides (e.g. stachyose and
raffinose) can cause flatulence. Besides the improvement
of the flavour of soybean products, fermentation can re-
duce flatulence (193), since lactic acid bacteria are able
to hydrolyze a-1,6-galactosidic linkages, releasing a-D-
-galactose (194) and making these products more digest-
ible. The survival of probiotics has been assayed in soy-
milk and this substrate has shown to be efficient for the
growth of species such as L. casei (195), L. acidophilus
(196), B. infantis, and B. longum (197). In addition, the
antioxidative activities of soymilk can be increased after
fermentation by lactic acid bacteria and bifidobacteria
(167). This has led to the designing of the probiotic soy-
bean yoghurt (198).
Application of Probiotics in Animal Feed
and Aquaculture
Animal feed companies and researchers have been
looking for alternative products and strategies that can
help to maintain animal gut health in order to prevent
or reduce the prevalence of pathogens in the food chain.
An alternative and effective approach to antibiotic ad-
ministration to livestock is the use of probiotics, which
can help to improve gut microbial balance and therefore
the natural defence of the animal against pathogenic bac-
teria (199,200).
In recent years, there has been a considerable inter-
est in using some probiotic microorganisms and organic
acids as an alternative to the use of antibiotics in feed.
Probiotics are viable microorganisms and supportive sub-
stances that, once ingested by humans and animals, pro-
duce beneficial physiological effects by assisting in the
establishment of an intestinal population which is bene-
ficial to the host's entity and antagonistic to harmful
bacteria. The natural adaptation of many lactic acid bac-
teria to the gut environment and the antimicrobial sub-
stances produced by them (organic acids and bacterio-
cins) has provided these organisms with a competitive
advantage over other microorganisms to be used as pro-
biotics (6,201).
The use of probiotics and commercial products con-
taining probiotics in aquaculture (e.g. shrimp production)
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has shown similar results compared to the antimicrobials
currently used (202). It could be an interesting alterna-
tive to overcome the problem of antibiotic resistance.
Multiple ways exist in which probiotics could be
beneficial and these could act either singly or in com-
bination forming a single probiotic. These include inhi-
bition of a pathogen via production of antagonistic com-
pounds, competition for attachment sites, competition
for nutrients, alteration of enzymatic activity of patho-
gens, immunostimulatory functions, and nutritional bene-
fits such as improving feed digestibility and feed utiliz-
ation (203–205). It is often reported that a probiotic must
be adherent and colonize within the gastrointestinal
tract, it must replicate to high numbers, it must produce
antimicrobial substances, and it must withstand the acid-
ic environment of the gastrointestinal tract (2,206–208).
Verschuere et al. (209) suggested a new definition of
a probiotic for aquatic environments: 'a live microbial
adjunct which has a beneficial effect on the host by mo-
difying the host-associated or ambient microbial commu-
nity, by ensuring improved use of the feed or enhancing
its nutritional value, by enhancing the host's response
towards disease, or by improving the quality of its am-
bient environment', or that 'a probiotic is an entire mi-
croorganism or its components that are beneficial to the
health of the host' (210). Table 3 (202,211–226) presents
the application of probiotic strains in animal nutrition,
during feed processing and aquaculture.
Probiotics and Prebiotics
In a recent review, Ranadheera et al. (227) reported
that food substrate/diet is considered as one of the ma-
jor factors in regulating colonization of microorganisms
in the gastrointestinal tract. Food helps to buffer the bac-
teria through the stomach and may contain other func-
tional ingredients that could interact with probiotics to
alter their functionality. Colonic foods, which encourage
the growth of favourable bacteria, are referred to as pre-
biotics. Oligosaccharides such as lactulose, galactooligo-
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Table 3. Application and effects of probiotics in animal feed and aquaculture
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facilitates increased mobilization of body reserves, increases milk fatty
acid production
218
S. cerevisiae camel feed increases total mass gain and improves feed utilization 219
S. cerevisiae buffalo feed increases digestion of cellulose 220





layer hens reduces mortality 222
L. sporogenes broiler chickens reduces serum total cholesterol and triglycerides 223
Lactobacillus ssp. chicken feed immunomodulating properties 224
Lactobacillus spp.,
Bacillus spp.
poultry feed reduces zoonosis in poultry meat 216
L. reuteri LPB P01-001 swine feed mass gain, antimicrobial activity against E. coli and S. aureus 225
Enterococcus faecalis,
E. faecium
canine feed bacteriocin-like inhibitory substances, antimicrobial activity against
Gram(+) bacteria, colonize transiently
226
saccharides, inulin, fructooligosaccharides, and other food
carbohydrates are some of the well known examples of
prebiotics. There is an obvious potential for a synergetic
effect when combining probiotics and prebiotics appro-
priately, because prebiotics promote the growth and ac-
tivities of probiotics. By increasing the amount of pre-
biotics in the diet, it is possible to increase and maintain
healthy bacterial gut flora in the host (228,229). Ingre-
dients in certain food products may naturally contain
prebiotics, which help to improve the functional efficacy
of probiotics. Many other foods such as dairy and meat
products, cereals, beverages and infant formulas can be
fortified with prebiotics during manufacturing process
to increase probiotic efficacy (230). In addition, a num-
ber of other suitable food components including non-
-specific substrates, plants and their extracts, metabolites
of microorganisms and polyunsaturated fatty acids may
also be important in probiotic efficacy (231).
The Technology of Probiotics
Probiotics are certainly very sensitive to many en-
vironmental stresses, such as acidity, oxygen and heat.
Before a probiotic can benefit human health, it must fulfill
several criteria related to the safety and stability (activ-
ity and viability in products; adherence; invasive poten-
tial; resistance to low pH, gastric juice, bile acid and
pancreatic juice; colonisation/survival in vivo) and func-
tional and physiological aspects (adherence to intestinal
ephitelium/tissue/virulence, antagonism to pathogenes,
antimicrobial activity, stimulation/supression of immune
response, selective stimulation of beneficial bacteria and
clinical side effects in voluteers/patients). The viability
of probiotics is a key parameter for developing probiotic
foods. Several factors shown in Fig. 1 affect the viability
of probiotic bacteria until they reach the target site of
the host (232).
A strain is commercially demanded for its tecnolo-
gical and health properties. Consequently, the search for
new technologies that enable high cell yield at large scale
and ensure probiotic stability in food remains strong,
because many strains of intestinal origin are difficult to
propagate and they must survive for economic and health
reasons. In addition, more efficient technologies could
lead to greater product efficacy and strain diversifica-
tion.
Some authors have presented developments in fer-
mentation technologies for producing probiotic bacteria
as well potential new approaches for enhancing the per-
formance of these organisms during fermentation, down-
stream processing, and utilization in commercial products,
and for improving functionality in the gut (232–234).
Until now, very few data have been reported on
continuous fermentations with probiotics, although this
approach could provide benefits, as recently reviewed by
Doleyres and Lacroix (233) for bifidobacteria. However,
continuous fermentations can be more difficult to ope-
rate under industrial conditions, because they are highly
susceptible to contamination and cell characteristics can
be lost over time. This technology is worth investigating
and could be used to produce cells with different phys-
iologies and to apply various stresses under well-con-
trolled conditions (232).
Membrane systems with continuous feeding of fresh
medium where cells are retained in the bioreactor by an
ultrafiltration or microfiltration membrane are also an
interesting technological possibility. In this case, small
molecules diffuse through the pores of the membrane
according to their size. Therefore, inhibitory metabolic
products are eliminated from the permeate and cells are
concentrated on the retentate side. The concentrated cell
fraction can be harvested batch-wise or continuously with
no, or minimal additional downstream treatment for cell
concentration before freezing or freeze drying.
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Fig. 1. Factors influencing the stability of probiotics during processing steps (adapted from Lacroix and Yildirim (232))
Different approaches that increase the resistance of
these sensitive microorganisms against adverse conditions
have been proposed, including appropriate selection of
acid- and bile-resistant strains, use of oxygen-imperme-
able containers, two-step fermentation, stress adaptation,
incorporation of micronutrients such as peptides and
amino acids, and microencapsulation (2). Lacroix and
Yildirim (232) reported that cell immobilization can be
used to perform high cell density fermentations for both
cell and metabolite production.
Microencapsulation is defined as a technology of
packaging solids, liquids or gaseous materials in mini-
ature, sealed capsules that can release their contents at
controlled rates under the influences of specific condi-
tions (235–237). A microcapsule consists of a semiperme-
able, spherical, thin, and strong membrane surrounding
a solid/liquid core, with a diameter varying from a few
microns to 1 mm (238). Encapsulation in hydrocolloid
beads entraps or immobilizes the cells within the bead
matrix, which in turn provides protection in such an en-
vironment (239). There are several techniques such as
spray drying, freeze drying, fluidized bed drying for
encapsulating the cultures and converting them into a
concentrated powdered form. However, the bacteria en-
capsulated by these techniques are completely released
in the product. In this case, the cultures are not protect-
ed from the product environment or during the passage
through the stomach or intestinal tract (240).
Food-grade polymers such as alginate, chitosan, car-
boxymethyl cellulose (CMC), carrageenan, gelatin and
pectin are mainly applied, using various microencapsu-
lation technologies (238). The most widely used encap-
sulating material is alginate, a linear heteropolysaccha-
ride of D-mannuronic and L-guluronic acids extracted
from various species of algae (241). Alginate beads can
be formed by both extrusion and emulsion methods
(238). The use of alginate is favoured because of its low
cost, simplicity, and biocompatibility (242–244). Other
materials used with the emulsion technique which avoid
the release of the cultures in the food product are a mix-
ture of k-carrageenan and locust bean gum (245–247),
cellulose acetate phthalate (248), chitosan (249), and gela-
tine (239–250).
Several factors, such as the capsule size (181), the
method of microencapsulation (251), the coating of the
capsules (252), the technological properties of probiotic
strains with regard to processing and heat stability, the
resistance of probiotic strains to the acidic conditions
present in the gut, and the presumed synergistic effects
of pro- and prebiotics by combining them in a single
product, have been observed to strongly influence the
viability of the probiotic cultures and, as a result, further
research is still needed in this area.
Microcapsules and microspheres can be engineered
to gradually release active ingredients (239). A micro-
capsule may be opened by many different means, in-
cluding fracture by heat, solvation, diffusion, and pres-
sure (253). A coating may also be designed to open in
the specific areas of the body. A microcapsule containing
acid-labile core materials that will be consumed by gas-
trointestinal fluids must not be fractured until after it
passes through the stomach. A coating must therefore be
used that is able to withstand acidic conditions in the
stomach and allows active ingredients to pass through
the stomach (237,254).
Several advantages of entrapped-cell over free-cell
fermentations have been demonstrated: high cell densi-
ties, reuse of biocatalysts, improved resistance to con-
tamination and bacteriophage attack, enhancement of
plasmid stability, prevention from washing-out during
continuous cultures, and the physical and chemical pro-
tection of cells (234). Table 4 (179–181,238,248,250–252,
255–281) presents some applications and properties of
immobilized probiotic cells.
Reliable and convenient biomarkers need to be de-
veloped for process monitoring and product assessment.
In this regard, the 'omics' technnologies could be parti-
cularly useful for identifying such functionality-relevant
biomarkers. These approaches could also help to iden-
tify the mechanisms for cell fitness and stress adapta-
tion, which will be needed to develop more generic and
science-based technologies for the production of sensi-
tive probiotics. This fact would surely enlarge the range
of commercial probiotics and product applications. More-
over, these tools might facilitate screening approaches to
identify new probiotic strains that combine suitable tech-
nological and functional qualities (232).
New Trends in Probiotic Products and Processing
In general, consumer's understanding of the poten-
tial benefits of foods containing viable bacteria/probiotics
is poor, particularly in the countries without a tradition
of cultured/sour dairy products. There are many barriers
to communicating messages about probiotics and the role
of diet in the gut flora modulation. However, in the
countries where there have been well planned educatio-
nal programmes among consumers and health profes-
sionals, the degree of awareness has increased (282,283).
In the future, health claims may help inform consumers
of the potential benefits, but it is crucial that appropriate
communication guidelines are adhered to and that all
claims are scientifically substantiated (14).
As it was presented by Reid (11), the number of
scientific publications on probiotics has doubled in the
past three years and this recent interest (284) has been
further stimulated by several factors: (i) exciting scien-
tific and clinical findings using well documented pro-
biotic organisms; (ii) concerns over limitations and side
effects of pharmaceutical agents; and (iii) consumer's de-
mand for natural products. The key to the future of pro-
biotics will be the establishment of a consensus on product
regulation, including enforcement of guidelines and stand-
ards, appropriate clinical studies that define strengths
and limitations of products, and basic science studies
that uncover the mechanisms of action of strains. Be-
sides, the molecular elucidation of the probiotic actions
in vivo will help to identify true probiotics and select the
most suitable ones for the prevention and/or treatment
of a certain illness (82). In fact, not only new probiotic
food must be developed, but the study and develop-
ment of new medications to combat diseases should be
continously performed.




























Table 4. Microencapsulation of probiotic bacteria using different technologies















































B. breve alginate microspheres emulsification acid stable 263
B. breve
B. longum
powder of freeze-dried culture micronization thermo/storage stable 264


















































































L. delbrueckii alginate/sodium lauryl sulphate gel beads biomass production 278
L. lactis gelatin/toluene-2,4-diisocyanate gel beads biomass production 250
L. reuteri Ca-alginate and k-carrageenan gel beads storage 279
P. acidilactici corn and olive oil microcapsules
emulsified by peptides
emulsification acid/storage stable 280
Conclusions
Probiotics have been extensively studied and ex-
plored commercially in many different products in the
world. Recent studies have suggested that probiotics
have demonstrated beneficial effects to human and ani-
mal health. Much of the clinical probiotic research has
been aimed at infantile, antibiotic-related and traveller's
diarrhoea. The non-pathogenic organisms used as pro-
biotics consist of a wide variety of species and subspe-
cies, and the ability to adhere, colonise and modulate
the human gastrointestinal system is not a universal pro-
perty. Lactobacillus and Bifidobacterium are the main pro-
biotic groups; however, there are reports on the probiotic
potential of yeasts. Some of the identified probiotic strains
exhibit anti-inflammatory, anti-allergic and other import-
ant properties. Besides, the consumption of dairy and non-
-dairy products stimulates the immunity in different
ways. Future research must investigate the mechanisms
by which gut microflora interacts with the intestinal epi-
thelium in health and disease. With this knowledge,
optimal probiotic strains can be developed. The viability
of probiotics is a key parameter for developing probiotic
food products. New technologies have been developed
to enable high cell yield at large scale and ensure pro-
biotic stability for a long period in food. Various food
matrices, dairy and non-dairy, have been used with pro-
biotics and were briefly documented. With different tech-
nologies, such as microencapsulation, cell immobilization
and continuous fermentation, the probiotics will become
an important and viable ingredient in the functional
foods, expanding the probiotic application outside the
pharmaceutical and supplement industries.
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